2004
DOI: 10.1097/01.cad.0000127664.66472.60
|View full text |Cite
|
Sign up to set email alerts
|

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

Abstract: Our objective was the preclinical assessment of the pharmacokinetics, monotherapy and combined antitumor activity of the epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor erlotinib in athymic nude mice bearing non-small cell lung cancer (NSCLC) xenograft models. Immunohistochemistry determined the HER1/EGFR status of the NSCLC tumor models. Pharmacokinetic studies assessed plasma drug concentrations of erlotinib in tumor- and non-tumor-bearing athymic nude mice. These were followed by maxi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
89
0

Year Published

2006
2006
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 138 publications
(94 citation statements)
references
References 12 publications
4
89
0
Order By: Relevance
“…Erlotinib, combined with chemotherapy, has also been studied in preclinical models of lung, pancreas, and head and neck cancer. When administered in combination with cisplatin and gemcitabine, erlotinib more effectively induced xenograft growth arrest, and this combination was more effective than either the chemotherapeutic agents or erlotinib alone (Higgins et al, 2004). Similar observations were previously reported regarding experimental chemosensitisation by EGFR blockade using mAbs, particularly C225.…”
Section: Egfr Targeting Plus Conventional Cytotoxic Agents From the Bsupporting
confidence: 76%
“…Erlotinib, combined with chemotherapy, has also been studied in preclinical models of lung, pancreas, and head and neck cancer. When administered in combination with cisplatin and gemcitabine, erlotinib more effectively induced xenograft growth arrest, and this combination was more effective than either the chemotherapeutic agents or erlotinib alone (Higgins et al, 2004). Similar observations were previously reported regarding experimental chemosensitisation by EGFR blockade using mAbs, particularly C225.…”
Section: Egfr Targeting Plus Conventional Cytotoxic Agents From the Bsupporting
confidence: 76%
“…Paclitaxel was obtained from Sigma Chemical Co. (St. Louis, MO) and administered at 200 Ag/wk, a dosing regimen that was selected on the basis of results of previous studies at our institution (14). Cisplatin was purchased from American Pharmaceutical Partners, Inc. (Schaumburg, IL) and was administered at 1.5 mg/kg/wk, a dose regimen that was previously reported in the literature (15). Propidium iodide and tetrazolium [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] were both purchased from Sigma Chemical.…”
Section: Methodsmentioning
confidence: 99%
“…EGFR TKIs combined with chemotherapy for advanced NSCLC in first-line setting Erlotinib improves the cytotoxic effects of chemotherapy in preclinical models [Higgins et al 2004]. So, it was proposed that combination of erlotinib and chemotherapy could further improve outcome of chemotherapy in patients with advanced NSCLC.…”
Section: Introductionmentioning
confidence: 99%